OncoCyte Corporation

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

The company believes that better and earlier detection of cancer through liquid biopsies will:


  • Improve patient outcomes
  • Increase the life expectancy of cancer patients
  • Significantly reduce health care costs

Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.

These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.

Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:

  • Simple
  • Accurate
  • Fast
  • Non-invasive

OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.

Type
Public
HQ
Alameda, US
Employees
9 (est)

OncoCyte Corporation Locations

Alameda, US

OncoCyte Corporation Metrics

OncoCyte Corporation Summary

Market capitalization

$177 M

Closing share price

$6.2

OncoCyte Corporation Market Value History

OncoCyte Corporation Company Life

You may also be interested in